Articles tagged with Cancer Vaccines
A new vaccine has been developed using a pathogen-mimicking approach, combining CpG 7909 adjuvant and synthetic peptide from melanoma antigen Melan-A/MART-1. The vaccine induced strong T cell responses in all eight patients, with one order of magnitude higher than previous studies.
Cancer researchers have developed a new method to delay dendritic cell activation, extending the time when immune cells can detect and attack cancer. By using a drug that links molecules, the approach prolongs the activity of dendritic cells, which are key to cancer vaccines.
Researchers found that a cancer vaccine can stimulate the production of CTLs against specific antigens and also reactivate spontaneously produced CTL populations against multiple cancer antigens in about 10% of patients with metastatic melanoma. This non-specific process could potentially eliminate bulk of tumor cells.
A genetically engineered listeria bacteria-based vaccine has shown promising results in targeting metastatic cancer cells, inducing a strong innate and acquired immune response. The vaccine, aiming to target pancreatic and ovarian cancers, could potentially be used to prevent recurrence after surgery and chemotherapy.
A new vaccine has induced antibodies and T cells targeting a specific cancer antigen, showing promise in delaying cancer recurrence. The NY-ESO-1/ISCOMATRIXTM vaccine demonstrated stronger responses compared to placebo or NY-ESO-1 protein alone.
Researchers found that cancer tumors reduce the release of interferon gamma and expression of perforin in CD8 T cells, disabling their ability to destroy cancer cells. However, these defects can be reversed with laboratory growth using immunological factors.
Researchers have identified SSX-2, a promising target for cancer vaccines, and found that patients mount their own immunological responses against cancer cells expressing the protein. A new early-phase clinical trial is underway to assess the safety and efficacy of an SSX-2-based vaccine.